Company: SCLXW
Filing Date: 2025-12-29
Form Type: 424B3
Source: 0001193125-25-335429
Chunk: 567

Company: Scilex Holding Co
Filing Date: 2025-12-29
Form: 424B3
Chunk 567
---
 | $                 |   2,470 |   |     | $    |       — |   |
| Exercise of December 2024 RDO Warrants in exchange for settlement of Tranche B Notes principal and 
 interest                                                                                           |     | $                 |   2,689 |   |     |      |       — |   |
| Purchase of equity investment in Datavault AI Inc in exchange for Bitcoin                          |     | $                 |   8,069 |   |     | $    |       — |   |
| Bitcoin acquired in exchange for shares of Semnur                                                  |     | $                 | 200,000 |   |     | $    |       — |   |
| Additions to intangible assets included in accrued expenses                                        |     | $                 |   1,000 |   |     | $    |       — |   |

See accompanying notes to unaudited condensed consolidated financial statements. F-63

SCILEX HOLDING COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Nature of Operations and Basis of Presentation

Organization and Principal Activities

Scilex Holding Company (“Scilex” and together with its controlled subsidiaries, the “Company”) is an innovative revenue-generating
company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company was originally formed in 2019 and currently has six
subsidiaries, of which the following four subsidiaries are wholly owned: Scilex Inc. (“Legacy Scilex”), Scilex Pharmaceuticals Inc. (“Scilex Pharma”), SCLX DRE Holdings LLC, and SCLX Stock Acquisition JV LLC (“SCLX
JV”); and the following two subsidiaries are controlled by Scilex: Scilex Bio, Inc. (“Scilex Bio”) and Semnur Pharmaceuticals, Inc. (“Semnur”). The business combination with Vickers (the “Scilex Business
Combination”) was closed in November 2022.

The Company launched its first commercial product in October 2018, ZTlido (lidocaine topical system)
1.8% (“ZTlido”), a prescription lidocaine topical system that is designed with novel technology to address the limitations of current prescription lidocaine therapies by providing significantly improved adhesion and continuous pain
relief throughout the 12-hour administration period. In June